Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 1
2005 1
2006 1
2007 1
2008 1
2009 2
2010 1
2017 3
2018 5
2019 2
2020 4
2021 1
2022 3
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
Cosentino F, Cannon CP, Frederich R, Cherney DZI, Dagogo-Jack S, Pratley RE, Mancuso JP, Maldonado M, Cater NB, Wang S, McGuire DK. Cosentino F, et al. Among authors: mancuso jp. Circulation. 2022 Aug 23;146(8):652-654. doi: 10.1161/CIRCULATIONAHA.121.058294. Epub 2022 Aug 22. Circulation. 2022. PMID: 35994565 Free PMC article. Clinical Trial. No abstract available.
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
Wojeck BS, Inzucchi SE, Neeland IJ, Mancuso JP, Frederich R, Masiukiewicz U, Cater NB, McGuire DK, Cannon CP, Yaggi HK. Wojeck BS, et al. Among authors: mancuso jp. Sleep Breath. 2023 May;27(2):669-672. doi: 10.1007/s11325-022-02594-2. Epub 2022 May 20. Sleep Breath. 2023. PMID: 35596030 Free PMC article. Clinical Trial.
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
Kim JM, Bhatt DL, Dagogo-Jack S, Cherney DZI, Cosentino F, McGuire DK, Pratley RE, Liu CC, Cater NB, Frederich R, Mancuso JP, Cannon CP. Kim JM, et al. Among authors: mancuso jp. Diabetes Obes Metab. 2023 May;25(5):1398-1402. doi: 10.1111/dom.14965. Epub 2023 Feb 14. Diabetes Obes Metab. 2023. PMID: 36594154 No abstract available.
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
Pandey A, Kolkailah AA, Cosentino F, Cannon CP, Frederich RC, Cherney DZI, Dagogo-Jack S, Pratley RE, Cater NB, Gantz I, Mancuso JP, McGuire DK. Pandey A, et al. Among authors: mancuso jp. Eur Heart J. 2023 Dec 21;44(48):5163-5166. doi: 10.1093/eurheartj/ehad639. Eur Heart J. 2023. PMID: 37864578 Free PMC article. No abstract available.
Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial.
Dagogo-Jack S, Pratley RE, Cherney DZI, McGuire DK, Cosentino F, Shih WJ, Liu J, Frederich R, Mancuso JP, Raji A, Gantz I. Dagogo-Jack S, et al. Among authors: mancuso jp. BMJ Open Diabetes Res Care. 2021 Oct;9(1):e002484. doi: 10.1136/bmjdrc-2021-002484. BMJ Open Diabetes Res Care. 2021. PMID: 34620621 Free PMC article. Clinical Trial.
Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Hollander P, Hill J, Johnson J, Wei Jiang Z, Golm G, Huyck S, Terra SG, Mancuso JP, Engel SS, Lauring B, Liu J. Hollander P, et al. Among authors: mancuso jp. Curr Med Res Opin. 2019 Aug;35(8):1335-1343. doi: 10.1080/03007995.2019.1583450. Epub 2019 Mar 25. Curr Med Res Opin. 2019. PMID: 30760125 Clinical Trial.
26 results